Navigation Links
How chemo kills tumors: research to reduce side effects
Date:8/6/2008

University of Manchester researchers are investigating exactly how chemotherapy drugs kill cancerous tumours in a bid to reduce side effects and test the effectiveness of safer new agents.

Dr Stephen Taylor and Karen Gascoigne at the University of Manchester's Faculty of Life Sciences have taken a new systematic approach to studying anti-mitotic drugs, which are used extensively for breast or ovarian cancer in the UK.

This class of drugs, which includes the agent taxol, has been used clinically for many years because they are highly effective. However, as in all chemotherapy, there are side effects. In the case of taxol these include peripheral neuropathies which can lead to permanent nerve damage and loss of sensation in fingers.

In addition little is known about how anti-mitotic drugs work, despite a lot of research on them, because many studies were population-based approaches that were indirect and led to vague and confusing interpretations.

Dr Taylor said: "To bypass the neurotoxicity, new anti-mitotics are being generated. Early clinical studies show that these drugs do not result in significant neurotoxicity. The big question now is whether they will have anti-tumour effects.

"To help determine this, we need to know which types of tumours are likely to be sensitive to these new agents, and which ones are likely to be resistant. This would allow clinicians to better design the clinical trials, i.e. you only recruit patients who are likely to respond. In addition, if the drugs show promise, then it would pave the way for patient stratification in the future, again allowing oncologists to identify which patients are likely to benefit from these drugs in advance of treatment.

"To predict which types of tumours are likely to respond, we first need to know how anti-mitotic drugs work, both the classical drugs and these new agents."

He and Ms Gascoigne, whose findings are published in the journal Canc
'/>"/>

Contact: Mikaela Sitford
Mikaela.Sitford@manchester.ac.uk
01-612-752-111
University of Manchester
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. TG2 identified as potential therapeutic target in chemo-resistant ovarian cancer
2. Mitochondrial cholesterol makes response to chemotherapy difficult in hepatic cancer
3. Herceptin and chemo improves response rates without major adverse effects in HER2 breast cancer
4. New chemotherapy combo produces side effects, but no extra efficacy, in early breast cancer patients
5. Standard chemo works better against metastatic BRCA1/2 breast cancer than against sporadic tumors
6. A search for protection against chemotherapy cardiotoxicity
7. UC health news: molecular pathway may predict chemotherapy effectiveness
8. Food scientists confirm commercial product effectively kills bacteria in vegetable washwater
9. New UGA invention effectively kills foodborne pathogens in minutes
10. Mounting evidence shows red wine antioxidant kills cancer
11. New decontamination system kills anthrax rapidly without lingering effects
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/9/2015)... , July 9, 2015  Synaptics Inc. (NASDAQ: SYNA ... today that it will report financial results for the ... 30, 2015 after the close of market. The company ... investors at 2:00 p.m. PT (5:00 p.m. ET), during ... To participate on the live call, analysts and investors ...
(Date:7/9/2015)... July 9, 2015  Unchained Labs just can,t ... acquisition of Avid Nano. Avid Nano designs, develops ... systems.    Also today, Unchained Labs ... easiest to use protein sizing system. The pUNk ... protein,s hydrodynamic size, size distribution, aggregation population and ...
(Date:7/8/2015)... , July 8, 2015 Summary ... and the fourth most fatal, with a mortality rate ... poor prognosis of pancreatic cancer patients has highlighted a ... which is not being met by the current market. ... array of products with varying molecule types and mechanisms ...
Breaking Biology News(10 mins):Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2Unchained Labs just can't get enough, acquires Avid Nano, rocks out the new pUNk! 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3
... When investigating cancer cells, researchers discovered numerous peculiarities: ... genes are overactive. Do these characteristics have a relation ... inactivate growth brakes or are they just a whim ... scientists perform what are called loss-of-function analyses. They knock ...
... the University of Hawaii Cancer Center and The Queen,s ... from the National Cancer Institute to develop novel methods ... analysis of gene expression and imaging data of the ... a research scientist at the UH Cancer Center, and ...
... An extreme form of pregnancy-related nausea and vomiting known ... of women each year and can lead to hospitalization and ... the only victims. A joint study by ... children whose mothers suffered from HG while carrying them were ...
Cached Biology News:A question of gene silencing 2Hawaii receives funding for liver cancer research 2Extreme morning sickness could lead to lifelong emotional, behavioral disorders in kids 2
(Date:7/28/2015)... 28, 2015  Moerae Matrix Inc. announced today ... trial with MMI-0100, a first-in-class inhibitor of MAPKAP ... pulmonary disorders characterized by inflammation and fibrosis.  The ... , is a double-blind, two-way cross-over design ... and tolerability of MMI-0100 when given via inhalation ...
(Date:7/28/2015)... ZIONA, Israel , July 28, ... OTC:CQPTY), a regenerative medicine company utilizing its proprietary ... announced that Shomrat Shurtz has been appointed Senior ...      (Photo: http://photos.prnewswire.com/prnh/20150728/246955 ) ... years of experience in marketing, regulatory and business ...
(Date:7/27/2015)... ... 27, 2015 , ... This is a professional and in-depth ... overview of the industry including definitions, classifications, applications and industry chain structure. The ... landscape analysis, and key regions development status. Development policies and plans are discussed ...
(Date:7/27/2015)... ... July 27, 2015 , ... ... network Monday. The venture will bring the world’s most efficient gas dissolution technology ... equipment and technologies to both the industrial and municipal markets. With offices located ...
Breaking Biology Technology:Moerae Initiates Lipopolysaccharide (LPS) Challenge Study of Inhaled MMI-0100 for Pulmonary Disease Following Encouraging Safety and Tolerability Observed in Single Ascending Dose Phase 1 Study 2CollPlant Names Shomrat Shurtz Senior Director of Business Development 22015 Biophotonics Market Global Research 22015 Biophotonics Market Global Research 3BlueInGreen Brings Water Treatment Technology to Florida 2
... the Americas -- The Agreement for Europe Will ... of DNA Extraction Kits -- ZyGEM,s Technology Enables ... Automation and High-Throughput Applications -SOLANA BEACH, Calif., and ... Corp. Ltd. and VWR International Europe bvba today ...
... EMERYVILLE, Calif., March 26 Neurobiological Technologies, Inc. (NTI(R)) ... has hired RBC Capital Markets as its exclusive financial ... to enhance shareholder value, including a potential sale of ... Capital Markets to assist us in efficiently determining if ...
... recent study using state-of-the-art genetic testing shows that an all natural skin ... Sirtuin-1, a key anti-aging gene. Until now only Resveratrol, a substance ... to naturally stimulate Sirtuin-1 in humans. Ambra-Lift™ contains no Resveratrol. ... ...
Cached Biology Technology:ZyGEM Corp. and VWR International Europe BVBA Sign Agreement to Distribute Breakthrough DNA Extraction Technology in Europe 2ZyGEM Corp. and VWR International Europe BVBA Sign Agreement to Distribute Breakthrough DNA Extraction Technology in Europe 3ZyGEM Corp. and VWR International Europe BVBA Sign Agreement to Distribute Breakthrough DNA Extraction Technology in Europe 4Neurobiological Technologies Announces Hiring of Advisor to Seek Sale of Company 2Genomic Study Shows Organic Skin Care Product Activates Key Anti-Aging Gene 2Genomic Study Shows Organic Skin Care Product Activates Key Anti-Aging Gene 3Genomic Study Shows Organic Skin Care Product Activates Key Anti-Aging Gene 4
... Anti-NY-ESO-1, clone E978 ... : NM_001327 Immunogen ... protein Formulation: mouse ascites ... Quality Assurance: routinely evaluated ...
... to Opsin 1 ( Abpromise for all ... peptide: YEDSTHASIFTYT, corresponding to amino acids 14/26 of ... corresponding to amino acids 18/30 of tiger red ... immunogen. Entrez Gene ID: ...
Goat polyclonal to p27 KIP 1 ( Abpromise for all tested applications). Antigen: Synthetic peptide: C-KRPATDDS STQNK, corresponding to Internal sequence amino acids 153-165 of Human p27 KIP 1 ...
Request Info...
Biology Products: